Role of the workplace in migraine disease management

Disease Management and Health Outcomes

Volumn 9, Issue 2, 2001, Pages 99-115

  Warshaw, L J ^a   Burton, W N ^a   Schneider, W J ^b  

^a Bank One   (United States)

^b JP Morgan Chase & Co   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ERGOT DERIVATIVE; SUMATRIPTAN;

CLINICAL TRIAL; DISEASE CONTROL; FEMALE; HEADACHE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; MALE; MANAGED CARE ORGANIZATION; MIGRAINE; NAUSEA; PATIENT EDUCATION; PHOTOPHOBIA; PREVALENCE; REVIEW; VOMITING; WORKPLACE;

EID: 0035103654     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200109020-00004     Document Type: Review

References (107)

1. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain
2. Impact of migraine in the United States: Data from the National Health Interview Study
3. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors
4. Medication use and disability among migraineurs: A national probability sample survey
5. Migraine prevalence. A review of population-based studies
6. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration
7. Migraine in the United States: A review of epidemiology and health care use
8. American migraine study II: Prevalence, burden and health care utilization for migraine in the United States
9. Prevalence of headache and migraine in school children
10. Migraine headaches in adolescents: A student population-based study in Monreale
11. Prevalence of migraine in a population of university students
12. The epidemiology of migraine in medical students
13. Economic and social impact of migraine
14. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine
15. Headache incidence in a hospital community
16. Cost benefit of sumatriptan to an employer
17. Quality of life and productivity in nurses reporting migraine
18. Migraine among doctors: Work loss and consumption of medication
19. Study of migraine and treatment of acute attacks in industry
20. A study of migraine and its effects in a working population
21. Prevalence and indirect costs of headache in a Brazilian company
22. Frequency of migraine among an unselected group of employees and variation of prevalence according to different diagnostic criteria
23. Loss of productivity and quality of life among French workers: Results from the GAZEL cohort
24. Comparative view of the socioeconomic impacts of migraine versus low back pain
25. Migraine impact and functional disability
26. Burden of migraine in the United States: Disability and economic costs
27. The burden of migraine: A review of cost to society
28. The economic cost of migraine. Present state of knowledge
29. Burden of migraine: A review of its socioeconomic impact
30. Migraine and reduced work performance; a population-based diary study
31. A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache
32. Impact of headache on sickness absence and utilisation of medical services: A Danish population study
33. Indirect costs in economic studies: Confronting the confusion
34. Social perspective on the burden of migraine in the Netherlands
35. The economic burden of migraine to society
36. Indirect costs of disease: An international comparison
37. Incremental absenteeism due to headaches in migraine: Results from the Mig-Access French national cohort
38. Socioeconomic and sex differentials in reason for sickness absence from the Whitehall II study
39. Lost workdays and decreased work effectiveness associated with headache in the workplace
40. Migraine: A problem for employers and managed care plans
41. The UK migraine patient survey: Quality of life and treatment
42. Migraine headache: Epidemiology and comorbidity
43. Treatment of severe disabling migraine attacks in an over-the-counter population of migraine sufferers: Results from three randomized, placebo-controlled studies of the combination of acetaminophen, aspirin and caffeine
44. Cost of migraine management a pharmacoeconomic overview
45. Guidelines for the diagnosis and management of migraine in clinical practice
46. Headache
47. Management of acute migraine attacks: Defining the role of sumatriptan
48. Efficacy and safety of acetoaminophen, aspirin and caffeine in alleviating migraine headache pain: Three double-blind, randomized, placebo-controlled trials
49. Sumatríptan: A pharmacoeconomic review of its use in migraine
50. Rizatriptan: A review of its efficacy in the management of migraine
51. Elitriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan. Elitriptan Steering Committee
52. Sumatriptan injection reduces productivity loss during a migraine attack: Results of a double-blind, placebo-controlled trial
53. Headache
54. Taking control of migraine and headache
55. Prophylactic pharmacotherapy of migraine: Some practical guidelines
56. Evidence based migraine prophylactic drug therapy
57. Migraine prophylactic drugs: Proof of efficacy, utilization and cost
58. Guidelines for the nonpharmacologic management of migraine in clinical practice. Canadian Headache Society
59. Clinical psychology issues in migraine headaches
60. Psychological impact: The personal burden of migraine
61. Developing disease management programs
62. Evidence-based disease management
63. Disease management
64. Interventions and outcomes management in migraine
65. Taking a disease management approach to migraine
66. Standards of care for treating headache in primary care practice. National Headache Foundation
67. Nurses' role in disease case management
68. Message tailoring: An essential component for disease management
69. Persons with chronic conditions, their prevalence and costs
70. The competitive advantage of a healthy work force: Opportunities got occupational health
71. High-cost analysis. A closer look at the case for work-site health promotion
72. Employees' sources of AIDS information: The workplace as a promising educational setting
73. Worksite AIDS education: A case study of the New York City police
74. Health protection and promotion: An overview
75. Worksite health protection
76. Health promotion in small organizations: The US experience
77. Triggers of headache episodes and coping responses of headache diagnostic groups
78. Precipitating factors in migraine: A retrospective review of 494 patients
79. Migraine trigger factors in non-clinical Mexican-American population in San Diego county: Implications for etiology
80. Perception of triggers in young nonclinical school students with migrainous headaches and with tension headaches
81. A computer-assisted health care cost management system
82. First Chicago's integrated health data management computer system
83. Health risk appraisal
84. Physical training and fitness programs: An organizational asset
85. Patient education and migraine: A pilot study
86. A pilot study of a headache program in the workplace: The effect of education
87. The doctor and the migraine patient: Improving compliance
88. Indirect costs of migraine in a managed care population
89. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: A managed care perspective
90. Sumatriptan treatment for migraine in a health maintenance organization: Economic, humanistic, and clinical outcomes
91. The role of health risk factors and disease on worker productivity
92. Validity of an illness severity measure for headache in a population sample of migraine sufferers
93. The migraine ACE model: Evaluating the impact on time lost and medical resource use
94. Validation of a migraine work and productivity questionnaire for use in migraine studies
95. Evolution of the measurement of quality of life in migraine
96. Development and validation of the migaraine-specific quality of life questionnaire
97. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: A managed care perspective
98. Improvements in health-related quality of life with sumatriptan treatment for migraine
99. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers
100. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score
101. Calculating return on investment from reducing workplace illness
102. Lost workdays and decreased work effectiveness associated with headache in the workplace
103. Impact of migraine and tension-type headache on lifestyle, consulting behaviour and medication use: A Canadian population survey
104. Management of migraine
105. Costs and benefits of prevention and disease management
106. Interventions and outcomes management in migraine
107. Cutting the costs of migraine: Role of the employee health unit